Australian Clinical Labs (ASX:ACL) NonCurrent Deferred Revenue: A$0.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ACL Australian Clinical Labs Ltd ASX:ACL
74 GF Score
Price A$2.86
GF Value A$2.95
Valuation Fairly Valued
! 9 Warning Signs
View Full Analysis

What is Australian Clinical Labs NonCurrent Deferred Revenue?

Australian Clinical Labs ASX:ACL -3.70% 74 NonCurrent Deferred Revenue is A$0.0 Mil as of Jun. 2026. GuruFocus rates ASX:ACL with a GF Score™ of 74/100 and a GF Value™ of A$2.95 (Fairly Valued). The stock has 9 warning signs investors should review.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Australian Clinical Labs's non-current deferred revenue for the quarter that ended in Jun. 2026 was A$0.0 Mil.

Australian Clinical Labs NonCurrent Deferred Revenue Related Terms

Australian Clinical Labs NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Australian Clinical Labs's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Australian Clinical Labs NonCurrent Deferred Revenue Chart

Australian Clinical Labs Annual Data
Trend Dec20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
NonCurrent Deferred Revenue
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Australian Clinical Labs Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:ACL
74GF Score
Australian Clinical Labs Ltd ASX:ACL
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of A$0.0 Mil mean?
Australian Clinical Labs (ASX:ACL) has a NonCurrent Deferred Revenue of A$0.0 Mil as of Jun. 2026. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Australian Clinical Labs and its competitors.
Is Australian Clinical Labs' NonCurrent Deferred Revenue too high?
Australian Clinical Labs' current NonCurrent Deferred Revenue is A$0.0 Mil. Overall, Australian Clinical Labs has a GF Score™ of 74/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' NonCurrent Deferred Revenue compare to TMO and DHR?
Australian Clinical Labs' NonCurrent Deferred Revenue of A$0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Medical Diagnostics & Research company?
A good NonCurrent Deferred Revenue depends on the Medical Diagnostics & Research industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Australian Clinical Labs and its competitors. Australian Clinical Labs's current NonCurrent Deferred Revenue is A$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Fairly Valued. The stock's GF Value™ is A$2.95, compared to a current price of A$2.86 — trading 3.1% below its estimated fair value. The current NonCurrent Deferred Revenue is A$0.0 Mil. Australian Clinical Labs' overall GF Score™ is 74/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current NonCurrent Deferred Revenue is A$0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?

Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued. The current stock price of A$2.86 is trading 3.1% below its estimated GF Value™ of A$2.95. GuruFocus considers Australian Clinical Labs to be Fairly Valued.

Key valuation signals for ASX:ACL:

  • NonCurrent Deferred Revenue: A$0.0 Mil
  • GF Value™: A$2.95 vs. price of A$2.86 (3.1% below fair value)
  • GF Score™: 74/100 with 9 warning signs

No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Australian Clinical Labs Business Description

Address 1868-1892 Dandenong Road, Clayton, VIC, AUS, 3168
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
74GF Score

Get the complete analysis for ASX:ACL

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.86
Price
A$2.95
GF Value